John Robert Perfect, MD

Professor of Medicine
James B. Duke Professor of Medicine
Chief, Division of Infectious Diseases
Professor in Molecular Genetics and Microbiology
Campus mail Duke Box 102359, Durham, NC 27710
Phone (919) 684-4016
Email address perfe001@mc.duke.edu

Research in my laboratory focuses around several aspects of medical mycology. We are investigating antifungal agents (new and old) in animal models of candida and cryptococcal infections. We have examined clinical correlation of in vitro antifungal susceptibility testing and with in vivo outcome. Our basic science project examines the molecular pathogenesis of cryptococcal infections. We have developed a molecular foundation for C. neoformans, including transformation systems, gene disruptions, differential gene expression screens, and cloning pathogenesis genes. The goal of this work is to use C. neoformans as a model yeast system to identify molecular targets for antifungal drug development. There are a series of clinical trials in fungal infections which are being coordinated through this laboratory and my work also includes a series of antibiotic trials in various aspects of infections. Finally, we have now been awarded a NIH sponsored Mycology Unit for 5 years with 6 senior investigators which is focused on C. neoformans as a pathogenic model system, but will include multiple areas of medical mycology from diagnosis to treatment.

Education and Training

  • Fellow, Infectious Diseases, Duke University School of Medicine, 1977 - 1980
  • Resident, University of Michigan at Ann Arbor, 1975 - 1977
  • Intern, Riverside Methodist Hospital, 1974 - 1975
  • M.D., University of Toledo, 1974

Publications

Carlson, A. N., G. N. Foulks, J. R. Perfect, and J. H. Kim. “Fungal scleritis after cataract surgery. Successful outcome using itraconazole..” Cornea 11, no. 2 (March 1992): 151–54.

PMID
1316256
Scholars@Duke

Goodwin, S. D., J. Fiedler-Kelly, T. H. Grasela, W. A. Schell, and J. R. Perfect. “A nationwide survey of clinical laboratory methodologies for fungal infections.” Medical Mycology 30, no. 2 (January 1, 1992): 153–60. https://doi.org/10.1080/02681219280000201.

Full Text

PERFECT, J. R., K. A. WRIGHT, and R. F. HECTOR. “SYNERGISTIC INTERACTION OF NIKKOMYCIN AND CILOFUNGIN AGAINST DIVERSE FUNGI.” In Recent Progress in Antifungal Chemotherapy, edited by H. YAMAGUCHI, G. J. KOBAYASHI, and H. TAKAHASHI, 369–79. MARCEL DEKKER, 1992.

Scholars@Duke

PERFECT, J. R. “CILOFUNGIN.” In Recent Progress in Antifungal Chemotherapy, edited by H. YAMAGUCHI, G. J. KOBAYASHI, and H. TAKAHASHI, 355–67. MARCEL DEKKER, 1992.

Scholars@Duke

Goodwin, S. D., J. Fiedler-Kelly, T. H. Grasela, W. A. Schell, and J. R. Perfect. “A nationwide survey of clinical laboratory methodologies for fungal infections..” Journal of Medical and Veterinary Mycology : Bi Monthly Publication of the International Society for Human and Animal Mycology 30, no. 2 (January 1992): 153–60.

PMID
1588465
Scholars@Duke

Persons, D. A., M. Laughlin, D. Tanner, J. Perfect, J. P. Gockerman, and J. W. Hathorn. “Fluconazole and Candida krusei fungemia..” N Engl J Med 325, no. 18 (October 31, 1991).

PMID
1922232
Scholars@Duke

PERFECT, J. R., M. G. RINALDI, M. G. WALSH, G. LOPEZBERESTEIN, R. SARAL, and R. D. DIAMOND. “FUNGAL-INFECTIONS IN THE IMMUNOCOMPROMISED HOST - DISCUSSION.” Reviews of Infectious Diseases 13, no. 3 (May 1, 1991): 504–8.

Scholars@Duke

Perfect, J. R., W. W. Pickard, D. L. Hunt, B. Palmer, and W. A. Schell. “The use of amphotericin B in nosocomial fungal infection..” Rev Infect Dis 13, no. 3 (May 1991): 474–79.

PMID
1866552
Scholars@Duke

Perfect, J. R. “Management of the immunocompromised patient: impact of fungal infections. Introduction..” Rev Infect Dis 13, no. 3 (May 1991).

PMID
1866551
Scholars@Duke

Perfect, J. R. “Discussion: Fungal infections in the immunocompromised host.” Reviews of Infectious Diseases 13, no. 3 (January 1, 1991): 504–8.

Scholars@Duke

Pages